Comparative Pharmacology
Head-to-head clinical analysis: PCE versus PROKLAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PCE versus PROKLAR.
PCE vs PROKLAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PCE (erythromycin) binds to the 50S subunit of bacterial ribosomes, inhibiting protein synthesis by blocking translocation of peptides.
PROKLAR (clarithromycin) is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, blocking peptide chain elongation.
Erythromycin ethylsuccinate (PCE) typical adult dose: 400 mg orally every 6 hours or 800 mg orally every 12 hours. Maximum 4 g/day.
500 mg orally every 12 hours for 7-14 days.
None Documented
None Documented
Terminal elimination half-life is approximately 3-5 hours in adults with normal renal function; may be prolonged to 7-10 hours in renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 2-4 hours (prolonged to 6-8 hours in hepatic impairment); context: requires q8-12h dosing in normal renal function
Primarily renal (about 70-80% as unchanged drug and metabolites via glomerular filtration and tubular secretion); minor biliary/fecal elimination (10-15%).
Renal: 20-30% unchanged; fecal: 15-30%; biliary: 5-10%; total renal excretion of metabolites: ~70%
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic